Request for Notification From Industry Organizations Interested in Participating in the Selection Process for Nonvoting Industry Representatives; Reopening of Notification Period, 22148 [2014-08968]

Download as PDF ehiers on DSK2VPTVN1PROD with NOTICES 22148 Federal Register / Vol. 79, No. 76 / Monday, April 21, 2014 / Notices AdvisoryCommittees/Calendar/ default.htm. Scroll down to the appropriate advisory committee meeting link. Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before May 13, 2014. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before May 5, 2014. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by May 6, 2014. Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact James Clark at James.Clark@fda.hhs.gov, or 301– 796–5293 at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/ AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm111462.htm for procedures on public conduct during advisory committee meetings. Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: April 15, 2014. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2014–08970 Filed 4–18–14; 8:45 am] BILLING CODE 4160–01–P VerDate Mar<15>2010 15:19 Apr 18, 2014 Jkt 232001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0001] Request for Notification From Industry Organizations Interested in Participating in the Selection Process for Nonvoting Industry Representatives; Reopening of Notification Period AGENCY: Food and Drug Administration, HHS. ACTION: Notice; reopening of comment period. The Food and Drug Administration (FDA) is reopening the period for industry organizations interested in participating in the selection of nonvoting industry representatives to represent the interests of the pharmaceutical manufacturing industry and the pharmacy compounding industry on the Pharmacy Compounding Advisory Committee for the Center for Drug Evaluation and Research to notify FDA of such interest. FDA announced a request for notification of interest in selection of industry representatives and for nominations in the Federal Register on January 13, 2014. This notice requested industry organizations that were interested in participation in the selection process to notify FDA in writing by February 12, 2014, and stated that nominations would be accepted for the two nonvoting vacancies by the same date. Industry organizations that did not notify FDA by the deadline of their interest in participating in the selection of nonvoting pharmacy compounding and pharmaceutical manufacturing industry representatives have now expressed interest in participating. Therefore, FDA is reopening the notification period for an additional two weeks so that any interested industry organizations wanting to participate can notify the Agency of their interest. DATES: Any industry organization interested in participating in the selection of appropriate nonvoting members to represent the interests of the pharmacy compounding industry and the pharmaceutical manufacturing industry on the Pharmacy Compounding Advisory Committee should send a letter stating the interest to FDA by May 5, 2014, for the vacancies announced in the Federal Register on January 13, 2014 (79 FR 2177). SUMMARY: PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 All letters of interest should be submitted electronically to PCAC@ fda.hhs.govmailto:, or in writing by mail to Jayne E. Peterson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Bldg. 31, Rm. 2417, Silver Spring, MD 20993. FOR FURTHER INFORMATION CONTACT: Jayne E. Peterson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993, 301–796– 9001, FAX: 301–847–8533, email: PCAC@fda.hhs.gov. This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees. ADDRESSES: Dated: April 15, 2014. Leslie Kux, Assistant Commissioner for Policy. [FR Doc. 2014–08968 Filed 4–18–14; 8:45 am] BILLING CODE 4160–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Fogarty International Center; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Fogarty International Center Advisory Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Fogarty International Center Advisory Board. Date: May 13, 2014. Closed: May 13, 2014 8:00 a.m. to 9:45 a.m. Agenda: To review and evaluate grant applications. E:\FR\FM\21APN1.SGM 21APN1

Agencies

[Federal Register Volume 79, Number 76 (Monday, April 21, 2014)]
[Notices]
[Page 22148]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-08968]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2013-N-0001]


Request for Notification From Industry Organizations Interested 
in Participating in the Selection Process for Nonvoting Industry 
Representatives; Reopening of Notification Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of comment period.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is reopening the period 
for industry organizations interested in participating in the selection 
of nonvoting industry representatives to represent the interests of the 
pharmaceutical manufacturing industry and the pharmacy compounding 
industry on the Pharmacy Compounding Advisory Committee for the Center 
for Drug Evaluation and Research to notify FDA of such interest. FDA 
announced a request for notification of interest in selection of 
industry representatives and for nominations in the Federal Register on 
January 13, 2014. This notice requested industry organizations that 
were interested in participation in the selection process to notify FDA 
in writing by February 12, 2014, and stated that nominations would be 
accepted for the two nonvoting vacancies by the same date. Industry 
organizations that did not notify FDA by the deadline of their interest 
in participating in the selection of nonvoting pharmacy compounding and 
pharmaceutical manufacturing industry representatives have now 
expressed interest in participating. Therefore, FDA is reopening the 
notification period for an additional two weeks so that any interested 
industry organizations wanting to participate can notify the Agency of 
their interest.

DATES: Any industry organization interested in participating in the 
selection of appropriate nonvoting members to represent the interests 
of the pharmacy compounding industry and the pharmaceutical 
manufacturing industry on the Pharmacy Compounding Advisory Committee 
should send a letter stating the interest to FDA by May 5, 2014, for 
the vacancies announced in the Federal Register on January 13, 2014 (79 
FR 2177).

ADDRESSES: All letters of interest should be submitted electronically 
to PCAC@fda.hhs.govmailto:, or in writing by mail to Jayne E. Peterson, 
Center for Drug Evaluation and Research, Food and Drug Administration, 
10903 New Hampshire Avenue, Bldg. 31, Rm. 2417, Silver Spring, MD 
20993.

FOR FURTHER INFORMATION CONTACT: Jayne E. Peterson, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993, 301-796-
9001, FAX: 301-847-8533, email: PCAC@fda.hhs.gov.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: April 15, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-08968 Filed 4-18-14; 8:45 am]
BILLING CODE 4160-01-P